Top 20 Oncology Companies of 2026 

Shots:  Merck & Co., Bristol-Myers Squibb, and Johnson & Johnson led the oncology market in 2025, generating $35.86B, $26.58B, and $25.38B, respectively. Growth was supported by strong demand for established therapies, newer product launches, and broader use across indications  The global oncology market is projected to grow from $279.73B in 2026 to $732.45B by 2035, at a CAGR of 11.31%. Rising cancer prevalence, targeted therapies, immunotherapies, advanced diagnostics, and AI-driven precision oncology continue to fuel growth. North America led the market in 2025, while Asia Pacific is expected to see strong expansion  The Top 20 Oncology Companies of 2026 ranks companies based on FY2025 oncology revenues and highlights their key products, revenue growth, major drivers, regulatory approvals, clinical developments, pipeline progress, and strategic collaborations  20. Eisai  Oncology Segment Revenue: $2.26B  Founded Year: 1941  Market Cap: $9.14B  Total Employees: 10,500  Headquarters: Tokyo, Japan  Stock Exchange: TYO  Eisai is a Japan-based pharmaceutical company with a strong focus on human health care, with oncology representing one of its core therapeutic areas. Its cancer portfolio spans multiple solid tumors and hematologic malignancies  Oncology revenue declined from $2.28B in 2024 to $2.26B in 2025, representing a 0.96% decrease, mainly reflecting stable performance across its established oncology portfolio. Key products included Lenvima/Kisplyx, Halaven, and Fycompa  In April 2026, Eisai and Merck reported data from the Phase 3 LITESPARK-012 study evaluating first-line combination treatments for patients with advanced renal cell carcinoma  19. Merck KGaA  Oncology Segment Revenue: $2.41B  Founded Year: 1668  Market Cap: $19.87B  Total Employees: 62,100  Headquarters: Darmstadt, Germany  Stock Exchange: ETR  Merck KGaA is a Germany-based science and technology company with a diversified healthcare business, with its pharmaceutical portfolio spanning oncology, neurology and immunology. Its oncology franchise is anchored by targeted therapies and immuno-oncology treatments  Oncology revenue increased from $2.38B in 2024 to $2.41B in 2025, representing a 1.20% increase, supported by steady demand for its established cancer medicines. Erbitux remained the largest contributor at $1.58B, followed by Bavencio at $0.82B   In May 2026, Merck KGaA announced that the first patient had been dosed in a Phase 3 study of an investigational antibody-drug conjugate for colorectal cancer, advancing its next-generation oncology pipeline  18. GSK  Oncology Segment Revenue: $2.68B  Founded Year: 2000  Market Cap: $134.44B  Total Employees: 68,800  Headquarters: London, United Kingdom  Stock Exchange: LON  GSK is a UK-based global biopharmaceutical company focused on developing medicines and vaccines, with its portfolio spanning respiratory, infectious diseases, HIV and specialty medicines, including oncology  Oncology revenue climbed from $1.9B in 2024 to $2.68B in 2025, representing a 40.57% increase, driven by continued growth across Zejula, Jemperli, and Ojjaara, while Blenrep added further momentum as its commercial opportunity expanded   In 2026, GSK announced an agreement to acquire a potential T-cell engager from Chimagen Biosciences for multiple myeloma, broadening its next-generation oncology pipeline  17. Bayer  Oncology Segment Revenue: $3.2B  Founded Year: 1863  Market Cap: $56.02B  Total Employees: 92,815  Headquarters: Leverkusen, Germany  Stock Exchange: ETR  Bayer is a Germany-based life sciences company focused on healthcare and agriculture, with its pharmaceutical business spanning prescription medicines across several therapeutic areas, including a growing oncology portfolio   Oncology revenue surged from $2.06B in 2024 to $3.2B in 2025, representing a 54.85% increase, driven largely by the continued growth of Nubeqa, which generated $2.8B, alongside contributions from Stivarga, Xofigo, and Vitrakvi  In September 2026, the US FDA granted accelerated approval to Hyrnuo (sevabertinib) as a first-line targeted therapy for patients with HER2-mutated non-small-cell lung cancer, adding a new precision-oncology asset to Bayer’s portfolio  16. Gilead Sciences  Oncology Segment Revenue: $3.23B  Founded Year: 1987  Market Cap: $185.61B  Total Employees: 17,000  Headquarters: California, United States  Stock Exchange: NASDAQ  Gilead Sciences is a US-based biopharmaceutical company focused on developing innovative medicines, with a broad portfolio spanning antiviral therapies, oncology, cell therapy and other specialty treatments  Oncology revenue declined from $3.28B in 2024 to $3.23B in 2025, representing a 1.61% decrease, with Yescarta ($1.49B) and Trodelvy ($1.39B) remaining the largest contributors to the franchise, alongside Tecartus  In July 2026, the EC CHMP recommended Trodelvy plus Keytruda for first-line treatment of PD-L1-positive metastatic triple-negative breast cancer, potentially expanding Trodelvy’s role in breast cancer  15. Takeda  Oncology Segment Revenue: $3.64B  Founded Year: 1781  Market Cap: $60.29B  Total Employees: 49,281  Headquarters: Tokyo, Japan  Stock Exchange: TYO  Takeda is a Japan-based global pharmaceutical company focused on innovative medicines, with a broad portfolio spanning oncology, gastroenterology, rare diseases, neuroscience and vaccines   Oncology revenue increased from $3.43B in 2024 to $3.64B in 2025, representing a 5.93% increase, supported by continued contributions from its established cancer portfolio. Key products included Leuplin/Enantone, Ninlaro, Adcetris, Velcade, and Alunbrig  In 2026, Takeda’s Fruzaqla (fruquintinib) continued to expand its commercial reach, with reimbursement announced in Ontario for patients with metastatic colorectal cancer  14. Daiichi Sankyo  Oncology Segment Revenue: $3.78B  Founded Year: 1899  Market Cap: $34.62B  Total Employees: 19,765  Headquarters: Tokyo, Japan  Stock Exchange: TYO  Daiichi Sankyo is a Japan-based global pharmaceutical company focused on innovative medicines, with oncology representing a core growth area. Its portfolio increasingly centers on antibody-drug conjugates targeting a range of solid tumors and hematologic malignancies   Oncology revenue jumped from $2.89B in 2024 to $3.78B in 2025, representing a 30.54% increase, driven by strong momentum across its ADC portfolio, particularly Enhertu, along with the launch of Datroway and continued contributions from Vanflyta   In August 2026, Daiichi Sankyo advanced DS-1025 into clinical development for patients with advanced solid tumors, adding a novel CD25-directed antibody-drug conjugate to its expanding oncology pipeline  13. Incyte  Oncology Segment Revenue: $4B  Founded Year: 2002  Market Cap: $25.22B  Total Employees: 2,840  Headquarters: Delaware, United States  Stock Exchange: NASDAQ  Incyte is a US-based biopharmaceutical company focused on discovering and developing medicines for serious diseases, with a specialized portfolio spanning oncology, inflammation and autoimmune conditions. Its cancer business is particularly focused on hematologic malignancies and selected solid tumors  Oncology revenue increased from $3.55B in 2024 to $4B in 2025, representing a 12.85% increase, led by Jakafi, which generated $3.09B, alongside royalties from Jakavi and contributions from Iclusig, Pemazyre, Monjuvi/Minjuvi, and Zynyz  In 2026, Incyte continued to streamline its development portfolio, prioritizing next-generation oncology programs and focusing resources on selected high-potential assets  12. BeOne Medicines Ltd.  Oncology Segment Revenue: $5.19B  Founded Year: 2010  Market Cap: $44.28B  Total Employees: 12,000  Headquarters: Basel, Switzerland  Stock Exchange: NASDAQ  BeOne Medicines, is a global biopharmaceutical company focused on developing and commercializing innovative cancer medicines, with a growing presence across hematologic malignancies and solid tumors   Revenue surged from $3.77B in 2024 to $5.19B in 2025, representing a 37.53% increase, driven primarily by Brukinsa, which generated $3.92B, while Tevimbra provided additional momentum across the company’s oncology portfolio   In July 2026, BeOne announced an expansion of its US manufacturing footprint with a total investment of more than $1B, supporting the production of its innovative cancer medicines  11. AbbVie  Oncology Segment Revenue: $6.62B  Founded Year: 2012  Market Cap: $468.50B  Total Employees: 57,000  Headquarters: Illinois, United States  Stock Exchange: NYSE  AbbVie is a US-based biopharmaceutical company focused on developing innovative medicines across immunology, oncology, neuroscience and other specialty areas, with its cancer portfolio spanning hematologic malignancies and solid tumors  Oncology revenue edged up from $6.55B in 2024 to $6.62B in 2025, representing a 1.02% increase. Imbruvica and Venclexta remained the largest contributors, while Epkinly and Elahere added momentum from newer oncology opportunities  In 2026, AbbVie expanded access to Elahere (mirvetuximab soravtansine) in Singapore for patients with platinum-resistant ovarian cancer, extending the reach of its antibody-drug conjugate  10. Amgen  Oncology Segment Revenue: $7.99B  Founded Year: 1980  Market Cap: $219.52B  Total Employees: 31,500  Headquarters: California, United States  Stock Exchange: NASDAQ  Amgen is a US-based biopharmaceutical company focused on developing innovative medicines for serious diseases, with a broad oncology portfolio spanning hematologic malignancies and solid tumors  Oncology revenue rose from $7.18B in 2024 to $7.99B in 2025, representing an 11.28% increase, supported by strong contributions from Xgeva, Blincyto, Kyprolis, and Vectibix, alongside growing sales of newer oncology medicines such as Imdelltra and Lumakras   In September 2026, the US FDA approved reduced monitoring time for the first two doses of Imdelltra (tarlatamab-dlle), potentially simplifying treatment administration for patients with small-cell lung cancer  9. Astellas Pharma  Oncology Segment Revenue: $8.14B  Founded Year: 1923  Market Cap: $27.47B  Total Employees: 14,754  Headquarters: Tokyo, Japan  Stock Exchange: TYO  Astellas Pharma is a Japan-based pharmaceutical company focused on developing innovative medicines across oncology, immunology, urology and other specialty areas, with oncology representing a key part of its global portfolio  Oncology revenue climbed from $7.03B in 2024 to $8.14B in 2025, representing a 15.90% increase, supported by continued demand for established brands and growth from newer therapies. Key products included Xtandi, Padcev, Xospata, and Vyloy  In 2026, Astellas dosed the first patient in a Phase 3 study of setidegrasib in previously treated patients with KRAS G12D-mutated advanced non-small-cell lung cancer, advancing its precision-oncology pipeline  8. Eli Lilly  Oncology Segment Revenue: $9.37B  Founded Year: 1876  Market Cap: $1.11T  Total Employees: 47,000  Headquarters: Indiana, United States  Stock Exchange: NYSE  Eli Lilly is a US-based pharmaceutical company focused on developing medicines across oncology, diabetes, obesity, neuroscience and immunology, with cancer therapies forming an important part of its specialty medicines portfolio  Oncology revenue increased from $8.75B in 2024 to $9.37B in 2025, representing a 7.12% increase, supported by continued demand for its established cancer medicines. Verzenio remained a central contributor, alongside Cyramza and Alimta   In 2026, the US FDA approved Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, expanding Lilly’s breast cancer portfolio  7. Novartis  Oncology Segment Revenue: $16.83B  Founded Year: 1996  Market Cap: $292.72B  Total Employees: 75,300  Headquarters: Basel, Switzerland  Stock Exchange: SWX  Novartis is a Switzerland-based pharmaceutical company focused on innovative medicines across oncology, immunology, cardiovascular-renal-metabolic diseases and neuroscience, with precision medicine and radioligand therapies forming key pillars of its cancer portfolio  Oncology revenue advanced from $14.29B in 2024 to $16.83B in 2025, representing a 17.72% increase, reflecting strong momentum across newer oncology assets and continued demand for established targeted therapies. Key products included Kisqali, Pluvicto, Scemblix, Tafinlar + Mekinist, and Jakavi  In June 2026, Novartis entered a new agreement with Antares Therapeutics to discover, develop and commercialize potential first-in-class cancer therapies, strengthening its external innovation strategy in oncology  6. Pfizer  Oncology Segment Revenue: $16.83B  Founded Year: 1849  Market Cap: $161.93B  Total Employees: 75,000  Headquarters: New York, United States  Stock Exchange: NYSE  Pfizer is a US-based pharmaceutical company focused on developing and commercializing innovative medicines and vaccines, with oncology forming a major part of its portfolio through targeted therapies and strategic acquisitions  Oncology revenue grew from $15.61B in 2024 to $16.83B in 2025, representing a 7.83% increase, supported by continued demand across its established cancer medicines and contributions from its expanded portfolio. Key products included Ibrance, Xtandi, Padcev, Inlyta, and Lorbrena  In May 2026, Pfizer and Innovent Biologics entered a global strategic collaboration to accelerate the development of innovative oncology medicines, expanding Pfizer’s external innovation efforts in cancer  5. Roche  Oncology Segment Revenue: $19.39B  Founded Year: 1896  Market Cap: $359.18B  Total Employees: 113,000  Headquarters: Basel, Switzerland  Stock Exchange: SWX  Roche is a Switzerland-based healthcare company that combines pharmaceuticals and diagnostics, with a strong focus on oncology and personalized healthcare. Its cancer portfolio spans breast, lung and other solid tumors through targeted therapies and immuno-oncology medicines  Oncology revenue rose from $17.53B in 2024 to $19.39B in 2025, representing a 10.61% increase, reflecting continued demand across its established cancer portfolio and growth from newer treatments. Key products included Herceptin, Perjeta, Tecentriq, Kadcyla, and Alecensa  In 2026, Roche received FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma who may be eligible for Ziihera, strengthening its precision-oncology approach  4. AstraZeneca  Oncology Segment Revenue: $23.69B  Founded Year: 1999  Market Cap: $340.07B  Total Employees: 96,100  Headquarters: Cambridge, United Kingdom  Stock Exchange: LON  AstraZeneca is a UK-based biopharmaceutical company focused on innovative medicines across oncology, biopharmaceuticals and rare diseases, with cancer therapies forming the centerpiece of its pharmaceutical portfolio  Oncology revenue increased from $20.27B in 2024 to $23.69B in 2025, representing a 16.88% increase, supported by broad-based growth across its oncology portfolio and continued demand for major targeted and immuno-oncology medicines. Key products included Tagrisso, Imfinzi, Lynparza, Calquence, and Enhertu  In 2026, AstraZeneca received US approval for Datroway as a first-line treatment for metastatic triple-negative breast cancer in patients who are not eligible for PD-1/PD-L1 inhibitors  3. Johnson & Johnson  Oncology Segment Revenue: $25.38B  Founded Year: 1886  Market Cap: $652.31B  Total Employees: 138,100  Headquarters: New Jersey, United States  Stock Exchange: NYSE  Johnson & Johnson is a US-based global healthcare company with a diversified portfolio spanning pharmaceuticals and medical technology, with oncology representing a major growth area within its Innovative Medicine business  Oncology sales rose from $20.78B in 2024 to $25.38B in 2025, representing a 22.13% increase. Growth was supported by strong demand for Darzalex and Erleada, expanded manufacturing capacity for Carvykti, and continued uptake of Tecvayli, Talvey, and Rybrevant/Lazcluze  In September 2026, J&J reported positive Phase 2b COPERNICUS results for Rybrevant FASPRO plus Lazcluze, supporting continued development of the combination in oncology  2. Bristol-Myers Squibb  Oncology Segment Revenue: $26.57B  Founded Year: 1887  Market Cap: $125.63B  Total Employees: 32,500  Headquarters: New York, United States  Stock Exchange: NYSE  Bristol Myers Squibb (BMS) is a US-based biopharmaceutical company focused on innovative medicines across oncology, hematology, immunology and other serious diseases, with cancer therapies forming a major part of its portfolio  Oncology revenue declined from $28.6B in 2024 to $26.57B in 2025, representing a 7.09% decrease, reflecting portfolio and product-mix pressures despite continued contributions from newer medicines. Key products included Opdivo, Yervoy, Breyanzi, Abecma, Revlimid, and Pomalyst  In 2026, BMS received US FDA accelerated approval for Zenbexus, its first CELMoD therapy, in combination with daratumumab/hyaluronidase and dexamethasone for patients with multiple myeloma as early as first relapse  1. Merck & Co.  Oncology Segment Revenue: $35.86B  Founded Year: 1891  Market Cap: $365.09B  Total Employees: 74,000  Headquarters: New Jersey, United States  Stock Exchange: NYSE  Merck & Co. is a US-based global pharmaceutical company focused on innovative medicines and vaccines, with oncology at the heart of its pharmaceutical portfolio and a broad presence across solid tumors and hematologic malignancies  Oncology revenue increased from $32.85B in 2024 to $35.86M in 2025, representing a 9.15% increase, driven primarily by higher Keytruda/Keytruda Qlex sales, alongside stronger contributions from Welireg, Lynparza, and Reblozyl. Keytruda/Keytruda Qlex alone generated $31.68B, up 7% year over year  In September 2026, Merck continued to expand the oncology potential of Welireg, building on its $710.0M in 2025 sales, which increased 41% year over year  Criteria:  The report is based on oncology segment revenues or revenues from oncology products reported for fiscal year 2025, encompassing established and next-generation cancer therapies to provide a comprehensive ranking of the world’s leading oncology companies.  For companies with non-December fiscal year-ends, revenues have been calculated for the January-December 2025 period using quarterly and annual financial filings. Where oncology-specific sales were not separately disclosed, estimates were derived from publicly available company reports and credible secondary sources.  Market capitalisation is considered as of 24 Sep 2026. Revenues reported in different currencies have been converted into US dollars using exchange rates as of 31 December 2025 to ensure consistency across all rankings.  Source:    Company Websites       Press Releases         Annual Reports        Quarterly Reports      Google Finance          OANDA        The post Top 20 Oncology Companies of 2026  appeared first on PharmaShots.